title: Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.
abstract: There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons, including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.
authors.affiliation: Department of Research, Mount Sinai Medical Center, Miami Beach, FL 33140, USA. dongmeiwu@bellsouth.net
authors.forename: Dongmei
authors.initials: D
authors.lastname: Wu
authors.forename: Dongwon
authors.initials: D
authors.lastname: Lee
authors.forename: Yong Kiel
authors.initials: YK
authors.lastname: Sung
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D065627:Familial Primary Pulmonary Hypertension; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D019141:Respiratory System Agents / Q000627:therapeutic use*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D019141:Respiratory System Agents; D014660:Vasoactive Intestinal Peptide